WallStreetZenWallStreetZen

NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jane HuangPresident CMO2025-04-043,355$0.68
$2.26kSell
Andrew CombsChief Chemistry Officer2025-03-25100,000$0.69
$69.30kBuy
Krishna VaddiCEO2025-03-25675,000$0.69
$467.77kBuy
Krishna VaddiCEO2025-03-2115,000$0.73
$10.97kBuy
Krishna VaddiCEO2025-03-205,416$0.73
$3.95kBuy
Krishna VaddiCEO2025-03-179,106$0.75
$6.83kBuy
Krishna VaddiCEO2025-03-1429,999$0.75
$22.62kBuy
Krishna VaddiCEO2025-03-1350,000$0.72
$35.80kBuy
Krishna VaddiCEO2025-03-1247,500$0.71
$33.73kBuy
Jane HuangPresident CMO2025-01-043,859$1.39
$5.36kSell

1 of 2

PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC19.78%10,909,256$9.83MInstitution
Baker Bros Advisors LP18.36%10,123,824$9.12MInstitution
Orbimed Advisors LLC17.73%9,776,491$8.81MInsider
David P. Bonita17.73%9,776,491$8.81MInsider
Baker Bros Advisors LP16.78%9,252,951$8.34MInsider
Krishna Vaddi4.88%2,693,625$2.43MInsider
Boxer Capital Management LLC3.10%1,708,187$1.54MInstitution
Blackrock Inc1.94%1,069,773$963.87kInstitution
Price T Rowe Associates Inc1.87%1,029,199$927.31kInstitution
Vanguard Group Inc1.83%1,010,392$910.36kInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD49.50%50.50%Net BuyingNet Buying
AVTX8.48%91.52%Net SellingNet Selling
CYCC0.34%97.50%Net SellingNet Selling
FBIO16.23%50.96%Net BuyingNet Buying
OKYO0.19%99.81%
View Top Biotech Stocks

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 58.32% institutional shareholders, 59.49% Prelude Therapeutics insiders, and 0.00% retail investors. Orbimed Advisors LLC is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 17.73% of the company. Orbimed Advisors LLC's Prelude Therapeutics shares are currently valued at $9.39M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.